Grufity logoGrufity logo

Acorda Therapeutics Inc Stock Research

ACOR

0.63USD0.00(0.00%)Delayed

Market Summary

USD0.630.00
Delayed
0.00%

ACOR Stock Price

ACOR RSI Chart

ACOR Valuation

Market Cap

15.2M

Price/Earnings (Trailing)

-0.14

Price/Sales (Trailing)

0.12

EV/EBITDA

0.44

Price/Free Cashflow

-0.56

ACOR Price/Sales (Trailing)

ACOR Profitability

EBT Margin

-61.03%

Return on Equity

-139.47%

Return on Assets

-26.87%

Free Cashflow Yield

-177.05%

ACOR Fundamentals

ACOR Revenue

Revenue (TTM)

124.1M

Revenue Y/Y

6.53%

Revenue Q/Q

7.92%

ACOR Earnings

Earnings (TTM)

-105.7M

Earnings Y/Y

48.82%

Earnings Q/Q

70.32%

Price Action

52 Week Range

0.261.86
(Low)(High)

Last 7 days

-37.5%

Last 30 days

-28.2%

Last 90 days

13.6%

Trailing 12 Months

-62.6%

ACOR Financial Health

Current Ratio

1.71

Debt/Equity

1.72

Debt/Cashflow

-0.22

ACOR Investor Care

Shares Dilution (1Y)

118.22%

Diluted EPS (TTM)

-6.82

Peers (Alternatives to Acorda Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
125.3B
26.3B
-2.75% 3.76%
19.12
4.76
1.32% 11.18%
99.6B
27.3B
-8.96% 41.01%
21.68
3.65
-0.09% -26.23%
58.4B
19.3B
-12.76% 1.00%
6.99
3.03
4.29% -31.47%
38.3B
10.2B
-9.67% 32.94%
12.57
3.76
-7.36% 95.80%
MID-CAP
9.1B
1.5B
-9.09% 3.35%
58.87
6.11
31.34% 72.43%
3.2B
108.5M
-21.10% -19.55%
-9.78
29.38
122.90% -12.19%
2.5B
60.9M
-18.47% -36.46%
-8.76
41.55
17.51% 22.00%
2.1B
107.9M
22.95% 67.45%
-4.29
19.27
54.84% 17.36%
SMALL-CAP
1.2B
112.0M
-14.86% -46.41%
-4.63
11.04
-70.76% -603.77%
1.1B
7.0M
-22.18% 24.65%
-7.11
158.97
131.81% -45.39%
541.9M
96.3M
-12.99% -82.24%
-1.92
5.63
72.44% -32.79%
513.7M
2.0B
-39.67% -92.01%
-0.78
0.26
72.89% 62.27%
355.3M
111.3M
-30.55% -58.78%
-1.85
3.19
0.54% -7.86%
101.4M
159.0K
-16.47% -82.96%
-0.97
637.62
-86.46% -64.56%
25.1M
-
94.03% -77.12%
-0.31
3.21
0.51% -185.61%

Financials for Acorda Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-4.4%118,566,000124,063,000122,008,000122,742,000129,071,000
  S&GA Expenses-2.0%106,256,000108,442,000115,068,000117,369,000124,399,000
  R&D Expenses-2.7%5,804,0005,968,0006,516,0007,365,00010,420,000
Costs and Expenses-10.1%153,906,000171,229,000187,194,000189,702,000208,109,000
EBITDA58.1%-12,640,000-30,149,000-64,055,000-76,139,000-
EBITDA Margin58.8%-0.10-0.25-0.52-0.59-
Earnings Before Taxes53.5%-35,247,000-75,720,000-93,458,000-96,734,000-109,074,000
EBT Margin20.3%-0.61-0.77-0.79-0.85-
Interest Expenses1.2%30,200,00029,839,00029,541,00029,772,00030,035,000
Net Income37.6%-65,916,000-105,671,000-118,888,000-95,070,000-104,000,000
Net Income Margin12.6%-0.85-0.97-0.77-0.81-
Free Cahsflow21.0%-26,887,000-34,033,000-28,273,000-41,513,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets0.6%396393406424455
  Current Assets14.5%82.0072.0077.0080.00102
    Cash Equivalents81.4%38.0021.0023.0032.0046.00
  Inventory-16.4%13.0015.0015.0015.0019.00
  Net PPE-7.9%3.003.003.004.004.00
  Current Liabilities-9.7%38.0042.0041.0046.0054.00
  Long Term Debt-151----
Shareholder's Equity23.6%94.0076.0088.00128151
  Retained Earnings2.0%-936-955-941-894-870
  Additional Paid-In Capital0.0%1,0301,0301,0291,0241,023
Accumulated Depreciation-35.00----
Shares Outstanding44.7%24.0017.0013.00--
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations21.8%-20.92-26.75-33.92-28.10-41.35
  Share Based Compensation-17.1%1.002.002.003.003.00
Cashflow From Investing47.7%-0.14-0.26-0.11-0.1874.00
Cashflow From Financing--69.65----

Risks for ACOR

What is the probability of a big loss on ACOR?

100%


Probability that Acorda Therapeutics stock will be more than 20% underwater in next one year

100%


Probability that Acorda Therapeutics stock will be more than 30% underwater in next one year.

91.5%


Probability that Acorda Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ACOR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Acorda Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ACOR

Cumulative Returns on ACOR

-43.3%


10-Year Cumulative Returns

-54.7%


7-Year Cumulative Returns

-66.6%


5-Year Cumulative Returns

-50.7%


3-Year Cumulative Returns

What are the long-term rolling returns for ACOR?

FIve years rolling returns for Acorda Therapeutics.

Annualized Returns

Which funds bought or sold ACOR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-06
Rockefeller Capital Management L.P.
new
-
-
-
-%
2023-02-16
IMA Wealth, Inc.
unchanged
-
13.00
13.00
-%
2023-02-15
Virtu Financial LLC
sold off
-100
-6,000
-
-%
2023-02-14
Royal Bank of Canada
reduced
-4.15
-
-
-%
2023-02-14
CANYON CAPITAL ADVISORS LLC
sold off
-100
-357,000
-
-%
2023-02-14
BRIDGEWAY CAPITAL MANAGEMENT, LLC
reduced
-24.58
28,810
58,810
-%
2023-02-14
PRUDENTIAL FINANCIAL INC
reduced
-47.84
6,074
24,074
-%
2023-02-14
TWO SIGMA ADVISERS, LP
added
1.35
7,501
11,501
-%
2023-02-14
Verition Fund Management LLC
reduced
-50.00
2,459
10,459
-%
2023-02-14
TWO SIGMA SECURITIES, LLC
added
554
107,748
114,748
-%

1–10 of 37

Latest Funds Activity

Are funds buying ACOR calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ACOR
No. of Funds

Acorda Therapeutics News

Trefis

Day 5 of Loss Streak for Acorda Therapeutics Stock with -39 ....

Trefis,
3 days ago

InvestorsObserver

The Washington Post

Acorda: Q4 Earnings Snapshot.

The Washington Post,
9 days ago

Thehour.com

Acorda: Q4 Earnings Snapshot.

Thehour.com,
9 days ago

Chron

Marketscreener.com

Business Wire

ESTEVE Launches INBRIJA® in Spain.

Business Wire,
11 days ago

Marketscreener.com

ESTEVE Launches INBRIJA® in Spain.

Marketscreener.com,
11 days ago

Schedule 13G FIlings of Acorda Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 10, 2023
davidson kempner capital management lp
0.21%
51,189
SC 13D/A
Feb 14, 2023
canyon capital advisors llc
0.00%
0
SC 13G/A
Feb 13, 2023
renaissance technologies llc
3.57%
868,892
SC 13G/A
Jan 23, 2023
davidson kempner capital management lp
0.24%
59,129
SC 13D/A
Jun 10, 2022
soros fund management llc
0%
0
SC 13G
Jun 10, 2022
davidson kempner capital management lp
0.28%
68,229
SC 13D
Feb 14, 2022
point72 asset management, l.p.
4.1%
464,276
SC 13G/A
Feb 14, 2022
ubs oconnor llc
0%
0
SC 13G/A
Feb 14, 2022
canyon capital advisors llc
5.79%
649,031
SC 13G/A
Feb 11, 2022
renaissance technologies llc
6.38%
714,156
SC 13G/A

ACOR Fair Value

Acorda Therapeutics fair value in different scenarios

The table shows the Fair Value estimates for Acorda Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

1.69

170.31%

1.79

186.31%

2.39

282.28%

3.58

472.62%

4.28

584.58%
Current Inflation

1.63

160.72%

1.72

175.11%

2.29

266.28%

3.38

440.63%

4.02

542.99%
Very High Inflation

1.55

147.92%

1.63

160.72%

2.15

243.89%

3.13

400.64%

3.70

491.81%

Historical Acorda Therapeutics Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Acorda Therapeutics

View All Filings
Date Filed Form Type Document
Mar 15, 2023
10-K
Annual Report
Mar 10, 2023
SC 13D/A
13D - Major Acquisition
Mar 09, 2023
8-K
Current Report
Feb 15, 2023
8-K
Current Report
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 13, 2023
SC 13G/A
Major Ownership Report
Jan 23, 2023
SC 13D/A
13D - Major Acquisition
Jan 05, 2023
8-K
Current Report
Jan 04, 2023
4
Insider Trading
Dec 23, 2022
8-K
Current Report

Latest Insider Trading transactions for ACOR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-09-03
Sabella Lauren M
sold (taxes)
-601
0.398
-1,511
chief operating officer
2022-09-03
Clem Kerry M
sold (taxes)
-601
0.398
-1,511
chief commercial officer
2022-03-17
COHEN RON
sold
-3,894
1.7014
-2,289
president and ceo
2021-09-03
COHEN RON
sold (taxes)
-17,257
4.38
-3,940
president and ceo
2021-09-03
Morales Robert
sold (taxes)
-1,962
4.38
-448
interim pao & pfo
2021-09-03
Sabella Lauren M
sold (taxes)
-6,618
4.38
-1,511
chief commercial officer
2021-03-03
Sabella Lauren M
acquired
-
-
11,125
chief commercial officer
2021-03-03
BLANK BURKHARD
acquired
-
-
11,125
cmo and head of r&d
2021-03-03
COHEN RON
acquired
-
-
29,000
president and ceo
2020-12-01
LAWRENCE DAVID
sold (taxes)
-737
0.6464
-1,141
chief, bus. ops & pao

1–10 of 47

Ronald Cohen
130
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

ACOR Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenues:  
Total net revenues$ 118,566$ 129,071
Costs and expenses:  
Cost of sales30,33240,787
Research and development5,80410,420
Selling, general and administrative106,256124,399
Amortization of intangible assets30,76430,764
Changes in fair value of derivative liability(37)(1,156)
Changes in fair value of acquired contingent consideration(6,659)2,895
Other operating income(12,554) 
Total operating expenses153,906208,109
Operating loss(35,340)(79,038)
Other income (expense), net:  
Interest and amortization of debt discount expense(30,200)(30,035)
Interest income1,9095
Realized Gain (Loss) on FX Currency(8) 
Gain on extinguishment of debt27,142 
Other income (expense)1,250(6)
Total other income (expense), net93(30,036)
Loss before taxes(35,247)(109,074)
Benefit from (Provision for) income taxes(30,669)5,120
Net loss$ (65,916)$ (103,954)
Net loss per share—basic$ (3.34)$ (9.79)
Net loss per share—diluted$ (3.34)$ (9.79)
Weighted average common shares outstanding used in computing net loss per share—basic19,70710,621
Weighted average common shares outstanding used in computing net loss per share—diluted19,70710,621
Net Product Revenues  
Revenues:  
Total net revenues$ 103,845$ 114,189
Royalty Revenues  
Revenues:  
Total net revenues14,221$ 14,882
License Revenue  
Revenues:  
Total net revenues$ 500 

ACOR Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 37,536$ 45,634
Restricted cash6,88413,400
Trade accounts receivable, net of allowances of $842 and $1,012, as of December 31, 2022 and 2021, respectively13,86617,002
Prepaid expenses4,3126,574
Inventory, net12,75218,548
Other current assets6,765999
Total current assets82,115102,157
Property and equipment, net of accumulated depreciation2,6034,382
Intangible assets, net of accumulated amortization305,087335,980
Right of use asset, net of accumulated amortization5,2876,751
Restricted cash2556,189
Other assets24811
Total assets395,595455,470
Current liabilities:  
Accounts payable9,80910,845
Accrued expenses and other current liabilities23,68028,605
Current portion of liability related to sale of future royalties 4,460
Current portion of lease liability1,5458,186
Current portion of acquired contingent consideration2,5321,929
Deferred revenue384 
Total current liabilities37,95054,025
Convertible senior notes167,031151,025
Derivative liability037
Non-current portion of acquired contingent consideration38,66847,671
Non-current portion of loans payable 27,645
Deferred tax liability44,20213,930
Non-current portion of lease liability4,3414,086
Other non-current liabilities9,7815,914
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value per share. Authorized 1,000,000 shares at December 31, 2022 and 2021; no shares issued as of December 31, 2022 and 2021 
Common stock, $0.001 par value per share. Authorized 61,666,666 shares at December 31, 2022 and 2021; issued 24,343,239 and 13,249,802 shares, including those held in treasury, as of December 31, 2022 and 2021, respectively2413
Treasury stock at cost (5,543 shares at December 31, 2022 and December 31, 2021)(638)(638)
Additional paid-in capital1,029,8811,023,136
Accumulated deficit(936,273)(870,357)
Accumulated other comprehensive loss628(1,017)
Total stockholders’ equity93,622151,137
Total liabilities and stockholders’ equity$ 395,595$ 455,470